At HMP Market Access Insights, we’re proud of the talented individuals who bring curiosity, creativity, and expertise to every project. One standout team member is Emma, who leads our research efforts for integrated delivery networks (IDNs). Beyond her professional acumen, Emma brings her unique flair as a baker, with a knack for crafting the perfect apple pie.
A Decade of Experience and Insights
With over 10 years of experience supporting academic health systems and IDNs, Emma has honed her ability to identify trends and deliver actionable insights that shape strategic decisions. Her approach combines rigorous analysis with an understanding of the health care system's complexities, ensuring our clients always receive valuable perspectives.
The Power of Curiosity and Collaboration
What sets Emma apart is her love for collaboration. She thrives in a team environment where curiosity drives innovation. “Our team’s collective curiosity makes the research process fun and the final product even more useful for our clients.”
Her passion for collaboration doesn’t just benefit the team—it directly translates to insights that resonate with clients, enabling them to make informed decisions in an ever-changing health care landscape.
From Data to Dessert
When Emma isn’t diving into data, she’s in the kitchen, channeling her creativity into baking. Her signature apple pie is a team favorite, showcasing her ability to blend precision and passion—qualities that shine in both her work and her hobbies.
Not only does Emma have over a decade of experience supporting academic health systems and integrated delivery networks (IDNs), but she’s also the go-to for a delicious apple pie.
Emma BijesseEasier access to oncology pathway recommendations encourages oncologists’ usage and considerations of these recommendations. Our new 2024-2025 Oncology Clinical Pathways Impact Report reveals the variability in pathway integration and usage.
Cindy ChenAs Oncology pathway programs continue to become more prominent in the marketplace, manufacturers are being challenged to assess how influential a specific pathway is.
Daniel Buchenberger